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Abstract
Background: Molecular data of histologically classified oligodendrogliomas are available offering the possibility to
stratify these human brain tumors into clinically relevant molecular subtypes.
Methods: Gene copy number, mutation, and expression data of 193 histologically classified oligodendrogliomas
from The Cancer Genome Atlas (TCGA) were analyzed by well-established computational approaches (unsupervised
clustering, statistical testing, network inference).
Results: We applied hierarchical clustering to tumor gene copy number profiles and revealed three molecular
subgroups within histologically classified oligodendrogliomas. We further screened these subgroups for molecular
glioma markers (1p/19q co-deletion, IDHmutation, gain of chromosome 7 and loss of chromosome 10) and found
that our subgroups largely resemble known molecular glioma subtypes. We excluded glioblastoma-like tumors
(7a10d subgroup) and derived a gene expression signature distinguishing histologically classified oligodendrogliomas
with concurrent 1p/19q co-deletion and IDHmutation (1p/19q subgroup) from those with predominant IDH
mutation alone (IDHme subgroup). Interestingly, many signature genes were part of signaling pathways involved in
the regulation of cell proliferation, differentiation, migration, and cell-cell contacts. We further learned a gene
regulatory network associated with the gene expression signature revealing novel putative major regulators with
functions in cytoskeleton remodeling (e.g. APBB1IP, VAV1, ARPC1B), apoptosis (CCNL2, CREB3L1), and neural
development (e.g.MYTIL, SCRT1,MEF2C) potentially contributing to the manifestation of differences between both
subgroups. Moreover, we revealed characteristic expression differences of several HOX and SOX transcription factors
suggesting the activity of different glioma stemness programs in both subgroups.
Conclusions: We show that gene copy number profiles alone are sufficient to derive molecular subgroups of
histologically classified oligodendrogliomas that are well-embedded into general glioma classification schemes.
Moreover, our revealed novel putative major regulators and characteristic stemness signatures indicate that different
developmental programs might be active in these subgroups, providing a basis for future studies.
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Background
Oligodendrogliomas belong to the class of diffuse gliomas
that represent the most frequent primary brain tumors
in adults [1]. About 4 to 8% of all diagnosed tumors of
the central nervous system are oligodendrogliomas [2].
Diffuse gliomas are generally characterized by infiltra-
tion of the surrounding brain tissue, and fast progression
and relapse are common [3]. Traditionally, histological
similarities to normal glial cells (astrocytes and oligo-
dendrocytes) were used to distinguish between different
types of diffuse gliomas according to the World Health
Organization (WHO) 2007 grading system [4]. Known
downsides of this histological classification include a con-
siderable variability of diagnoses between neuropatholo-
gists and difficulties in discriminating oligodendrogliomas
from other types of diffuse gliomas like astrocytomas and
“mixed-type” oligoastrocytomas, which complicates diag-
nostics and treatment decisions for individual patients
[5, 6]. These challenges led to the exploration of molec-
ular markers for glioma diagnostics [7]. The majority of
oligodendrogliomas shows a characteristic allelic loss of
chromosomal arms 1p and 19q (1p/19q) that contributes
to better chemotherapy sensitivity and longer recurrence-
free survival [8, 9]. Three different gene expression
subtypes of 1p/19q co-deleted oligodendrogliomas have
recently been revealed, but the analysis of the clinical rel-
evance of these subtypes requires additional studies [10].
Further, specific heterozygous somatic point mutations of
the isocitrate dehydrogenase gene (IDH1/2) were found
in more than three-fourths of all oligodendrogliomas and
nearly three-fourths of all astrocytomas of WHO grades
II and III [11–13] and in all 1p/19q codeleted gliomas
[14]. These mutations are associated with the glioma-CpG
island methylator phenotype (G-CIMP) [15, 16] and with
a better prognosis compared to IDH wild-type tumors
[11, 17].
These molecular markers were integrated into a recent
update of the classification of tumors of the central ner-
vous system by the WHO [18]. As a consequence, some
diffuse glioma classes became obsolete, like the “mixed-
type” oligoastrocytomas that should now be classified as
either oligodendrogliomas or astrocytomas. According to
this new classification, oligodendrogliomas are charac-
terized by the co-occurrence of the mutation of IDH1/2
and the 1p/19q co-deletion. Notably, this class does not
accommodate IDH-mutated tumors with 1p/19q wild-
type that were classified as oligodendrogliomas based on
histology before. Such discrepancies between histologi-
cal and molecular tumor classification still remain a great
challenge for further improvements of glioma diagnos-
tics, but in terms of prognosis molecular markers can
outweigh histological characteristics. Recently, it has been
shown that glioma subgroups can be defined based on
IDH mutation and 1p/19q co-deletion status deriving
genetic subgroups that are more reflective of disease
subtypes than glioma classes defined by histology [19].
These results were further refined through the analysis
of DNA methylation profiles revealing clinically relevant
molecular subtypes [20]. In addition, single cell transcrip-
tome data has allowed to gain novel insights into the
molecular architecture of oligodendrogliomas showing
that themajority of tumor cells express either a specialized
astrocyte-like or oligodendrocyte-like program, whereas
a subpopulation of cells remains undifferentiated and is
associated with a neural stem cell expression program
that most likely drives tumor development [21]. This has
been further extended by analyzing single cell transcrip-
tomes of oligodendrogliomas and astrocytomas suggest-
ing a common stemness program for both tumor types
that drives tumor growth, whereas differences between
both types are mainly driven by the tumor microen-
vironemt and specific genetic signatures [22]. This has
important consequences for the clinical management of
oligodendrogliomas and may also explain in part differ-
ences between molecular and histological classifications.
All these and many other studies have greatly contributed
to a better understanding of molecular characteristics
of oligodendrogliomas. Still, also in the light of differ-
ences between histological and molecular classifications,
our knowledge about specific molecular characteristics of
oligodendrogliomas is incomplete.
Here, we present an in-depth computational analysis
of histologically classified oligodendrogliomas from The
Cancer Genome Atlas (TCGA) revealing novel differences
between molecular subgroups at the level of individual
genes, pathways, and gene regulatory networks. We first
stratified these tumors based on their gene copy number
profiles into three subgroups utilizing unsupervised clus-
tering. Additional screening for the presence of known
glioma markers showed that these subgroups largely
resembled already known molecular glioma subtypes. To
further characterize molecular differences, we derived a
signature of differentially expressed genes distinguishing
tumors with 1p/19 co-deletion and IDH mutation from
tumors that predominantly showed an IDH mutation. We
further learned a gene regulatory network that is capa-
ble to explain this observed expression signature. This
enabled us to identify novel putative major regulators that
are potentially involved in the manifestation of differences
between both subgroups. Interestingly, this network also
contained a characteristic expression signature of HOX
and SOX genes that distinguishes both subgroups indicat-
ing the activity of different glioma stemness programs.
Methods
Molecular data of oligodendrogliomas and normal brains
DNA copy number, RNA-seq gene expression, and
somatic mutation data was obtained from the TCGA
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data portal (https://gdc.cancer.gov/) for 193 histologically
classified oligodendrogliomas of the TCGA lower grade
glioma (LGG) cohort (Additional file 1). The vast majority
of tumor samples represented primary tumors, except
five recurrent tumors. We determined gene-specific copy
number log-ratios for each oligodendroglioma based on
its corresponding DNA copy number profile (see [23]
for details). Three commercially available normal brain
samples were obtained from StrataGen, BioChain, and
Clonetech for which RNA-seq gene expression has been
measured previously. All considered gene copy (17,677
genes) and gene expression (15,988 genes) profiles are
provided in Additional file 2.
Clustering based on CNV data
Hierarchical clustering (euclidean distance, complete link-
age) of tumors was done in R using the processed gene
copy number variation (CNV) log-ratio data of tumor
compared to normal. One obvious outlier (TCGA-P5-
A5F6-01A) was removed from subsequent analyses. Three
tumor subgroups were derived by cutting the clustering
dendrogram into three sub-trees. These subgroups were
named taking into account the following molecular prop-
erties: (i) 1p/19q - co-deletion of chromosomal arms 1p
and 19q and presence of characteristic IDH1/2 mutation,
(ii) IDHme - predominance of IDH1/2 mutation but no
co-deletion of 1p and 19q, and (iii) 7a10d - no co-deletion
of 1p and 19q, lack of IDH1/2 mutations, amplification of
chromosome 7, and deletion of chromosome 10.
Data normalization and identification of differentially
expressed genes
Raw RNA-seq gene expression counts were loaded into
R. Combined normalization of tumor and normal brain
RNA-seq data was done using the voom function of the
limma package [24] with normalization method cyclic
loess. Differential gene expression analysis between CNV-
derived tumor subgroups was done following limma’s
standard workflow. Differentially expressed (signature)
genes were selected using an FDR-adjusted p-value (q-
value) [25] cut-off of 0.01.
Verhaak and G-CIMP classification
Gene expression log2-ratios of genes in tumor compared
to the average expression in normal brain tissue were
computed for each oligodendroglioma sample. 756 of 840
genes that were used to derive the four Verhaak classes
[26] were part of our data set. We calculated pearson
correlation and associated p-values between the gene
expression log-ratios in the glioma reference set and our
tumor subgroups. Similarly, 42 of 50 genes of the glioma-
CpG islandmethylator phenotype (G-CIMP) set [15] were
part of our data set, for which we calculated Pearson
correlations and p-values. Note that genes missing from
the Verhaak and G-CIMP signature do not strongly affect
the classification, because there are other genes in these
signatures that show expression levels that are strongly
correlated with those of the missing genes [27].
Survival analysis
Information about days to death or days to last follow-up
was taken fromTable S1 of [20]. This table represented the
most recent survival information in months at the time of
our study. We transformed the survival information from
months into days using the factor 30.4167 followed by
a rounding to the nearest integer (Additional file 1). We
generated survival curves and performed log-rank tests
using the R package survival [28].
Gene and pathway annotation enrichment analysis
Gene, signaling, and metabolome pathway annotations
were obtained from [23]. The number of signature genes
per annotation category was counted separately for up-
and downregulated genes, and the significance of gene
enrichment was calculated using Fisher’s exact test.
Signature-specific regulatory network inference
We inferred transcriptional regulatory networks associ-
ated with the normalized expression of the signature genes
that discriminate between the 1p/19q and IDHme sub-
groups following the approach detailed in [27] with few
modifications. We constructed two types of networks that
differed in the set of predictor variables: (i) only the gene
copy number of a signature gene was used to predict its
own expression and (ii) in addition to the copy numbers,
the gene expression of all signature genes that were anno-
tated as transcription factors (TFs) were used to predict
the expression of a signature gene. The expression value
of a particular TF was excluded from its own prediction
in the latter analysis. For each signature gene, lasso (least
absolute shrinkage and selection operator) regression [29]
and a significance test for lasso [30] were used to estimate
the coefficients and their corresponding significance for
each predictor of the underlying signature gene-specific
linear model as implemented in [31]. We only considered
the most significant predictors with p-values less than
5 × 10−5 specified by the standard detection limit of the
covariance test implementation [30]. We further validated
each network through cross-validation by repeated ran-
dom subsampling. To this end, the data was randomly
partitioned into a training set constituting two-third of
the tumors on which the network was constructed and a
test set constituting the remaining one-third of tumors for
which the expression of the signature genes was predicted
and compared to the experimentally measured expres-
sion. This was repeated 100 times. To assess prediction
accuracy we calculated pearson correlation of predicted
and measured gene expression averaged over the 100
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networks. For network visualization we only kept links
that occurred in at least 75% of the 100 networks.
Results
Gene copy number variations and IDHmutations
characterize three molecular subgroups of histologically
classified oligodendrogliomas
It has been shown previously that the majority of histo-
logically classified oligodendrogliomas has a co-deletion
of chromosomal arms 1p and 19q and a characteristic
mutation of IDH1/2 [19, 32]. We thus analyzed genome-
wide gene copy number data that were available for 193
histologically classified oligodendrogliomas from TCGA
(Additional files 1 and 2). Unsupervised clustering of the
tumors based on their CNV profiles alone revealed three
subgroups (Fig. 1). We further analyzed the mutation sta-
tus of IDH1/2 of tumors in these subgroups (Table 1).
The largest subgroup comprised 133 tumors (68.9%) and
showed the characteristic 1p/19q co-deletion as well as
IDH1 or IDH2 mutations in each tumor. We refer to
this subgroup as 1p/19q. The second largest subgroup
included 45 tumors (23.3%) that showed no obvious pat-
tern of gene deletions or amplifications. Since themajority
of tumors in this subgroup had an IDH1/2 mutation
(82%), we named this subgroup IDH mutation-enriched
(IDHme). The third subgroup comprised 15 tumors (7.8%)
that were characterized by an amplification of chromo-
some 7 and a deletion of chromosome 10 as typically
observed in classical glioblastomas [3]. Only three tumors
in this subgroup had an IDH1 or IDH2 mutation (20%).
Fig. 1 CNV-derived molecular subgroups of histologically classified oligodendrogliomas. Heatmap of genome-wide gene copy number log-ratios of
193 histologically classified oligodendrogliomas (columns) compared to normal brain for 17677 genes (rows); blue: deletions, gray: unchanged, red:
amplifications. Chromosomes are highlighted by alternating gray and black bars to the left; chromosome midpoints are indicated by labels to the
right. Oligodendroglioma subgroups were revealed by unsupervised clustering and are shown using green (1p/19q), yellow (IDHme), and red
(7a10d) column coloring. Tumors of WHO grade II are labeled in light purple. WHO grade III is labeled in dark purple. Tumors with an IDH1/2
mutation are labeled in dark brown. The absence of an IDH mutation is labeled in light brown
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Table 1 Frequency of mutations of known cancer-relevant
genes per oligodendroglioma subgroup
Gene Mutated 1p/19q IDHme 7a10d
IDH1/2 Yes 133 37 3
No 0 8 12
TP53 Yes 7 35 6
No 126 10 9
ATRX Yes 3 30 3
No 130 15 12
CIC Yes 85 2 0
No 48 43 15
FUBP1 Yes 38 0 0
No 95 45 15
NOTCH1 Yes 31 3 0
No 102 42 15
We refer to this subgroup as 7a10d. It is important to
note that the 7a10d subgroup formed an own subcluster
that is relatively distant to the 1p/19q and IDHme sub-
groups, which were both part of one larger subcluster
(Fig. 1).
Tumors of the three subgroups differ in mutational status
of other cancer-relevant genes
We further observed differences in mutational profiles of
known glioma-relevant genes (TP53, ATRX, CIC, FUBP1,
NOTCH1 [3, 19]) between tumors of the three subgroups
(Table 1). Only 5% and 2% of the 1p/19q tumors showed
a mutation of, respectively, TP53 and ATRX, while about
two-third of the IDHme tumors had at least one of these
two genes mutated. For 7a10d tumors, these numbers
were 40% and 25%, respectively. In contrast, CIC and
FUBP1 were relatively frequently mutated in the 1p/19q
subgroup (64% and 29%, respectively), but only two CIC
and no FUBP1 mutations were observed in the IDHme
tumors and none of the 7a10d tumors showed CIC and
FUBP1 mutations. Also for NOTCH1 the IDHme and
7a10d subgroups resemble each other in terms of muta-
tion frequency (7% and 0%, respectively), while about
one-fourth of the 1p/19q tumors showed a NOTCH1
mutation.
Subgroup 7a10d differs in Verhaak and G-CIMP subtype
classification and patient survival from 1p/19q and IDHme
In order to explore whether tumors of the three oligo-
dendroglioma subgroups differ in their gene expres-
sion profiles compared to known molecular glioma sub-
types we first considered the Verhaak subtypes [26]. We
computed the correlation between the given signature-
specific expression levels of the Verhaak subtypes and
the corresponding gene expression levels of each individ-
ual oligodendroglioma. We observed moderate but still
significant correlation values with the Verhaak subtypes
for the vast majority of tumors (P <0.05 for 130 of 133
1p/19q tumors, for 43 of 45 IDHme tumors, and for all
7a10d tumors considering the Verhaak subtype with the
strongest correlation). The 1p/19q and IDHme subgroups
showed a similar association pattern (Fig. 2a top and mid-
dle). Tumors in both subgroups have highest similarity
to the proneural and classical subtypes followed by the
mesenchymal subtype, while there is generally a nega-
tive correlation with the neural subtype. In contrast, the
vast majority of tumors in the 7a10d subgroup had a
negative correlation with the proneural subtype (Fig. 2a
bottom). This is expected for tumors without an IDH
mutation [15].
In a similar analysis, we compared the associations of
the three oligodendroglioma subgroups with the expres-
sion signature of the G-CIMP subtype driven by the muta-
tion of IDH [15]. Like for the Verhaak classification, the
1p/19q and IDHme subgroups resembled each other and
the tumors in these subgroups had generally positive cor-
relation values to G-CIMP (P <0.1 for 73 of 133 1p/19q
tumors and 27 of 45 IDHme tumors), as opposed to 7a10d
tumors that showed no or very weak positive and negative
correlation (P <0.1 for 2 of 15 tumors, Fig. 2b).
We also analyzed whether there are differences in
patient survival between the three subgroups by using
the clinical data available for 125 1p/19q, 34 IDHme, and
15 7a10d tumors. Patients from the 1p/19q and IDHme
subgroups showed no differences in survival (Fig. 2c top
and middle, log-rank test, P = 0.7843). In sharp con-
trast, patients from 7a10d showed significantly shorter
survival than patients from the 1p/19q and IDHme sub-
groups (Fig. 2c bottom, log-rank tests, P = 4.9×10−6 and
P = 1.1 × 10−4, respectively) consistent with previous
findings [19].
All three subgroups are part of known glioma subtypes
Recent studies have defined molecular subtypes for
gliomas [19, 20]. We thus analyzed how our three sub-
groups 1p/19q, IDHme, and 7a10d observed for his-
tologically classified oligodendrogliomas are embedded
in these general classification schemes. Diffuse gliomas
were grouped into three major subtypes based on the
IDH mutation status and the presence of the 1p/19q co-
deletion in [19]. Our 1p/19q subgroup corresponds to the
1p/19q subtype in [19]. The IDHme subgroup is included
in the subtype that has no 1p/19q co-deletion but an
IDH mutation in [19]. The 7a10d subgroup is included
in the subtype that has no IDH mutation and no 1p/19q
co-deletion, which contains gliomas of which about 50%
showed a gain of chromosome 7 and a loss of chromo-
some 10 [19]. Further, our purely CNV-based derivation
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Fig. 2 Oligodendroglioma subgroup comparison. a Pearson correlation between the expression log-ratios of 756 marker genes in the Verhaak
glioma reference set and our tumor subgroups is shown for the four Verhaak classes. b Pearson correlation between the expression log-ratios of 42
genes in the G-CIMP reference set and our tumor subgroups. c Kaplan-Meier curves (solid lines) and 95%-confidence intervals (dashed lines) of
patient survival according to the corresponding clinical data
of the three subgroups (Fig. 1) shows that tumors with an
IDHmutation are more similar to each other than tumors
without an IDHmutation. This is in accordance with [19].
Also highly similar gene mutation patterns and survival
times are observed for our subgroups and those by [19].
The classification scheme in [19] has been refined in
[20] subdividing the IDH mutant group into a G-CIMP-
low, G-CIMP-high, and a 1p/19q co-deletion subtype. Our
1p/19q subgroup is included in the 1p/19q co-deletion
group in [20]. Further, the vast majority of tumors in
our IDHme subgroup belong to the G-CIMP-high group
in [20] indicated by the observation of positive correla-
tions with the G-CIMP subtype in our analysis (Fig. 2b
middle). Only four IDHme tumors may belong to the G-
CIMP-low subtype (correlation with G-CIMP less than
0.1, Fig. 2b middle). This is in good accordance with the
molecular classification of histologically classified oligo-
dendrogliomas by [20]. In addition, the non-IDH mutant
group was further subdivided in [20] into a classic-like,
mesenchymal-like, and two other subtypes. Tumors of
our 7a10d subgroup are represented by these subtypes.
About half of the 7a10d tumors belong to the classic-like
group (Fig. 2a bottom). The majority of the remaining
tumors belong to the mesenchymal-like group, but they
also show a relatively strong correlation with the classical
group (Fig. 2a bottom). This is similar to [20] where also
a large proportion of the tumors in the mesenchymal-like
group were classified to belong to the classical group of
Verhaak [26].
We further tested if the three subgroups were well-
embedded in molecular data of closely related histolog-
ically classified oligoastrocytomas and astrocytomas of
the TCGA lower grade glioma cohort. Therefore, we per-
formed unsupervised clustering of the gene copy number
profiles and found that all three subgroups were present
among the oligoastrocytomas and that the astrocytomas
were split up into the IDHme and 7a10d subgroup. In
addition, Verhaak and G-CIMP subtype classifications,
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patient survival, and gene expression behavior were highly
similar between the oligodendroglioma subgroups and
corresponding subgroups of oligoastrocytomas and astro-
cytomas (Additional file 3). This clearly indicates that each
of our derived subgroups was adequately covered based
on molecular data of histologically classified oligoden-
drogliomas.
Generally, strong differences in chromosomal muta-
tions, subtype characteristics, and patient survival
between the 7a10d subgroup and the other two sub-
groups 1p/19q and IDHme (Figs. 1 and 2) indicate that
7a10d tumors rather resemble glioblastoma-like tumors
[3, 19, 20]. We therefore focused our further analysis on
the comparison of tumors from the 1p/19q and IDHme
subgroups.
A signature of differential gene expression discriminates
1p/19q from IDHme
To compare genome-wide gene expression profiles of
the 1p/19q and IDHme subgroups we conducted a dif-
ferential gene expression analysis contrasting these two
subgroups. Using a q-value cut-off of 0.01 we identified
5113 genes to be differentially expressed between 1p/19q
and IDHme (Fig. 3, Additional file 4). The expression of
half of the signature genes was downregulated in 1p/19q
compared to IDHme, while the other half was upregu-
lated. When comparing tumors of grade II and grade III
within each subgroup we found no large-scale differences.
Only 104 signature genes where differentially expressed
between tumor grades II and III for the 1p/19q sub-
group (73 grade II vs. 60 grade III tumors, Additional
file 5), while there were no significant expression differ-
ences of signature genes between tumor grades II and
III for the IDHme subgroup (33 grade II vs. 12 grade
III tumors).
The signature is enriched for signaling andmetabolic
pathway genes and transcription factors
Looking at the annotations of the 5113 signature genes
we found that the categories transcription factor/cofactor,
kinase, phosphatase, signaling pathway gene, and tumor
suppressor gene were significantly enriched for downreg-
ulated genes in tumors of the 1p/19q subgroup compared
to that of the IDHme subgroup (P <0.05, Fig. 4). For sig-
nature genes upregulated in 1p/19q compared to IDHme
only the transcription factor/cofactor category was found
to be significantly enriched (P <0.1). Among the affected
signaling pathways several pathways known to be involved
in cancer were significantly enriched with genes downreg-
ulated in 1p/19q tumors compared to IDHme (Fig. 4c).
These were the MAPK signaling, ErbB signaling, mTOR
signaling, PI3k-Akt signaling, Apoptosis, Wnt signaling,
TGF-Beta signaling, VEGF signaling, Focal adhesion,
Adherence junction, Jak-STAT signaling, and Hedgehog
Fig. 3 Gene signature distinguishing 1p/19q from IDHme. The
heatmap shows the expression values of 5113 differentially expressed
(q-value <0.01) signature genes (rows) for 178 histologically classified
oligodendrogliomas (columns). Rows are Z-score-scaled and ordered
based on a hierarchical clustering of the data (dendrogram not
shown). Subgroups are shown in green (1p/19q) and yellow (IDHme)
with tumor grades highlighted using light (grade II) and dark (grade
III) shadings. Genes that are located on chromosomal arms 1p or 19q
are indicated by black lines to the left of the heatmap; other genes
are in gray
signaling pathway, which are known to affect prolifera-
tion, differentiation, migration, adhesion, cell growth and
survival, cell cycle arrest and progression, andmetabolism
(see Table S4 in [33]). For genes upregulated in 1p/19q no
enrichment of signaling pathways was observed.
Regarding metabolic pathways (Fig. 4b), the pentose
phosphate pathway (generating NADPH, pentoses, and
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Fig. 4 Functional analysis of signature genes. Enrichment of gene categories (a), metabolic pathways (b), and signaling pathways (c) with signature
genes. Bars are shown separately for genes down- and upregulated in 1p/19q compared to IDHme using blue and red color, respectively.
Significance of enrichment was calculated using Fisher’s exact test and is highlighted by asterisks symbols
Ribose 5-phosphate, a precursor for nucleotide synthesis)
and inositol phosphate pathway (generating inositol phos-
phates that play a role in various cellular processes includ-
ing cell growth and differentiation, cell migration and
apoptosis) were significantly enriched with genes down-
regulated in 1p/19q (P <0.05 and P <0.01, respectively).
The pyrimidine pathway (generating cytosine, thymine,
and uridine nucleotides) was enriched with genes showing
an increased expression in 1p/19q tumors (P <0.01).
Moreover, there were in total 1006 transcription fac-
tors/cofactors present in the signature (Additional file 6),
forming the basis for the subsequent reconstruction of
a gene regulatory network that is associated with the
observed expression differences between the 1p/19q and
IDHme subgroups.
A gene regulatory network is associated with expression
differences between 1p/19q and IDHme
We sought to construct a gene regulatory network which
can predict the expression of the 5113 signature genes
distinguishing 1p/19q from IDHme. In this analysis, 100
cross-validated networks were computed and used to cal-
culate an average predicted expression value for each
signature gene (see “Methods” for details). We applied the
approach to two different predictor sets. First, we started
to learn a network for which only the copy number of a
gene was used to predict its expression. For 1442 signature
genes (28.2%) no prediction of gene expression based on
the underlying gene copy number was obtained. For the
vast majority of the remaining signature genes the aver-
age predicted expression value correlated positively with
the measured expression for the test data (Fig. 5a), and the
median correlation coefficient over all signature genes was
0.292 (P <0.05 for 53.7% of the genes).
In the second analysis, we learned a regulatory network
by utilizing both the gene-specific copy numbers and the
expression values of transcription factors that were part
of the signature as predictors. This network yielded sig-
nificantly better predictions than the CNV-only network
(Fig. 5a, Mann-Whitney U test, P ≈ 0). Predictions were
obtained for all signature genes, and the median corre-
lation coefficient was 0.676 on the test data (P <0.05
for 95.8% of the genes). We chose this second network
(Additional file 7) for further analysis because of its supe-
rior prediction accuracy and the possibility to identify
potential regulators of other signature genes.
Hubs in the network, e.g. nodes with high degree that
have many connections to other nodes, may help to iden-
tify potential key regulators involved in the manifestation
of differences between the 1p/19q and IDHme subgroups.
We thus looked at the out-degree of nodes represent-
ing transcription factors and found that few of them
(49 of 1006, 4.9%) had an out-degree of at least 10, while
the vast majority were connected to few signature genes
(Fig. 5b). A sub-network containing only these hub tran-
scription factors and the signature genes connected to
them by ingoing or outgoing links is shown in Fig. 6. The
vast majority of network connections represent activating
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Fig. 5 Regulatory network predictions and hub transcription factors. a Pearson correlations between predicted and measured expression of the
5113 signature genes on the test data are shown for the network utilizing only gene copy number data (CNV: dark-turquoise) and the network
utilizing both gene copy number and gene expression data (CNV + EXP: light-turquoise) as predictors. Correlation values are averaged over 100
cross-validation iterations (see Methods for details). b Ranking of transcription factors by out-degree for the CNV + EXP network. Only very few
transcription factors have high out-degree values (hubs), whereas the large majority shows few connections to other signature genes
links. Moreover, this sub-network can be further par-
titioned into potential gene regulatory modules that (i)
show many internal connections, (ii) have few or no
external links to other gene clusters, and (iii) comprise sig-
nature genes with comparable patterns of expression dif-
ferences between 1p/19q and IDHme (see node coloring
in Fig. 6).
Regulatory hubs and gene network modules affect
cancer-relevant functions
One of the gene modules in our regulatory network
(Fig. 6) contains APBB1IP, the gene with the highest out-
degree in the network, as well as other hub transcription
factors including VAV1, ARPC1B, SPI1, TFEC, FERMT3,
and IKZF1, among others. The expression of genes in this
cluster is downregulated in 1p/19q compared to IDHme.
According to GeneCards [34] and UniProtKB/Swiss-Prot
[35] annotations, APBB1IP functions in signal transduc-
tion from Ras activation to actin cytoskeletal remodeling
[36, 37], VAV1 is a guanine nucleotide exchange factor
for Rho family GTPases also known to be involved in the
regulation of cytoskeletal rearrangements and a known
proto-oncogene [38], ARPC1B regulates actin polymer-
ization and mediates the formation of branched actin net-
works [39], SPI1 is a proto-oncogene potentially involved
in the regulation of pre-mRNA splicing [40], TFEC has
been associated with breast cancer and is part of the
cancer-related C-MYB transcription factor network [41],
FERMT3 has been associated with cell adhesion deficien-
cies [42], and IKZF1 is known to be involved in different
types of cancer [43].
A second gene module includes the hub transcription
factors CDK5R2, MYT1L, CELF3, RGS7, and SCRT1
(Fig. 6). In contrast to the first gene cluster described
above, the expression of genes in this second cluster is
upregulated in 1p/19q compared to IDHme. CDK5R2 is
a regulator of the cell division protein Cyclin-dependent
kinase 5 and has been associated with neuronal migration
and development [44], MYT1L is a pan-neural transcrip-
tion factor involved in neuronal differentiation and is
thought to play a role in the development of neurons and
oligodendroglia [35], CELF3 is involved in the regulation
of pre-mRNA alternative splicing [45], RGS7 is associated
with benign neoplasms in different organs and regulates
G-protein-coupled receptor signaling [46], and SCRT1 is
a Zinc finger DNA-binding protein critical for neuronal
differentiation [47].
There are other individual hub transcription factors in
the network with potentially relevant functions in can-
cer development. One of them is PHB (upregulated in
1p/19q compared to IDHme) that codes for prohibitin,
which inhibits DNA synthesis, has been associated with
breast cancer, and plays a role in regulating prolifera-
tion [48, 49]. CREB3L1 (upregulated in 1p/19q) is thought
to be involved in the protection of astrocytes from ER
stress-induced cell death [50]. CENPT (upregulated in
1p/19q) encodes one of the inner kinetochore proteins
and is required for normal chromosome organization
and progress through mitosis [51].MEF2C (dowregulated
in 1p/19q) is crucial for normal neuronal development
and has been suggested to be involved in neurogenesis
and in the development of cortical architecture [52, 53].
EIF3K (downregulated in 1p/19q) is a component of the
eukaryotic translation initiation complex regulating pro-
tein synthesis [54]. CCNL2 (downregulated in 1p/19q)
regulates a critical factor involved in cell apoptosis [55].
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Fig. 6 Gene regulatory network distinguishing 1p/19q from IDHme Sub-network showing transcription factors with an out-degree of at least 10 and
the signature genes connected to them. Genes (nodes) are colored according to gene expression log-ratios between the average expression in
1p/19q and IDHme. Nodes with labels represent transcription factors and the size of a node is proportional to its out-degree. Activating and
repressing links are shown in yellow and green color, respectively, and transparency of a link is inversely proportional to the number of times the link
is present across the 100 cross-validation iterations
Further, ETV4 involved in developmental processes and
oncogenesis [34] was upregulated in 1p/19q compared to
IDHme.
Comparison of 1p/19q and IDHme to closely related
oligodendrogliomas and astrocytomas
Recently, bulk and single cell transcriptomes of IDH-
mutant oligodendrogliomas and astrocytomas have been
compared [22]. This study suggested shared glial lineages
and developmental hierarchies where most differences
resulted from characteristic mutations and microenvi-
ronmental compositions. In more detail, they observed
that differences in bulk gene expression profiles between
oligodendrogliomas and astrocytomas can be primar-
ily explained by the impact of characteristic tumor
class-specific mutations (oligodendrogliomas: 1p/19q co-
deletion, CIC mutations; astrocytomas: TP53 mutations)
and differences in the composition of the tumor microen-
vironment, but not by distinct expression programs of
glial lineages of malignant cells. They compared oligoden-
drogliomas defined based on their histology and the pres-
ence of the 1p/19q co-deletion to astrocytomas defined
based on their histology and the presence of mutations in
TP53 or ATRX. This is similar to our analysis. Our 1p/19q
subgroup has the same histological and genetic features as
their oligodendrogliomas. Our IDHme subgroup is closely
related to their astrocytomas, except for differences in
histology. In accordance with [22], we observed downreg-
ulations of genes on 1p and 19q (Fig. 3) and upregulations
of genes of the p53 signaling pathway (Fig. 4c) in 1p/19q
compared to IDHme. We found similar evidences that
genes involved in cytoskeleton remodeling (e.g. APBB1IP,
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VAV1, ARPC1B, Fig. 6) were downregulated in 1p/19q
compared to IDHme, which might indicate potentially
existing morphological differences. Further, we found
significant expression differences between 1p/19q and
IDHme analyzing oligodendrocyte-like and astrocyte-
like expression programs from [22] (Additional file 8:
Figure S1A-B, t-test, P = 4.8 × 10−11). The 1p/19q
subgroup showed higher expression of genes of the
oligodendrocyte-like program than the IDHme subgroup,
whereas IDHme showed higher expression of genes of the
astrocyte-like program. Similarly, both groups also dif-
fered in their expression of microglia/macrophage marker
genes (Additional file 8: Figure S1C, t-test, P <0.03). Inter-
estingly, we found a weak trend that the 1p/19q and
IDHme subgroups differ in the expression of the stem-
ness program from [22]. Still, the majority of genes of
the stemness program showed similar expression levels in
both groups, but there were several genes with stronger
expression differences (Additional file 8: Figure S1D).
This included genes involved in cytoskeleton remod-
eling (absolute average log-ratio for 1p/19q compared
to IDHme >1; DCX,TMSB15A: upregulated in 1p/19q;
FNBP1L: downregulated in 1p/19q) andMYT1L, a known
key factor of neural differentiation, upregulated in 1p/19q
compared to IDHme.
1p/19q and IDHme tumors differ in stemness programs
Glioma stemness programs have been characterized over
the last years suggesting important regulatory roles
for different members of the HOX [20, 56] and SOX
[20–22, 57] gene families. Roles of SOX genes in devel-
opment and pathology have been reviewed in [58]. We
thus analyzed our regulatory network (Additional file 7)
for characteristic expression differences of both gene fam-
ilies between 1p/19q and IDHme. Our network includes
seven HOX genes (HOXA4, HOXA5, HOXA6, HOXA7,
HOXA11, HOXA13, HOXC4) and four SOX genes (SOX6,
SOX8, SOX12, SOX13). Interestingly, all HOX genes were
downregulated in 1p/19q compared to IDHme, whereas
all SOX genes were upregulated in 1p/19q compared to
IDHme (Fig. 7). This indicates the activity of different
stemness programs between 1p/19q (potentially SOX-
driven) and IDHme (potentially HOX-driven) tumors.
Moreover, this is also supported by already known
cancer-relevant functions of different genes. HOXA4
overexpression suppressed cell motility and spreading in
ovarian cancer [59]. HOXA5 downregulation increased
stemness, cell plasticity and aggressiveness of breast can-
cer [60], and upregulation induced stemness loss in colon
cancer [61]. HOXA7 overexpression enhanced prolifera-
tion, migration, invasion and metastasis of liver cancer
[62].HOXA11was reported to represent a potential tumor
suppressor in different cancers [63, 64]. HOXC4 overex-
pression of was observed in lymph node metastases of
prostate cancer [65]. Interestingly, different SOX genes
have already been reported to be involved in oligoden-
drocyte development. Alterations of corresponding gene
expression patterns can therefore be important for tumor
development. SOX6 regulates different stages of oligo-
dendrocyte development by repressing cell specification
and terminal differentiation and by influencing cell migra-
tion patterns [66]. SOX8 is expressed in immature glia of
the developing cerebellum and in cerebellar tumors [67]
and has important functions in oligodendrocyte devel-
opment and differentiation [68, 69]. SOX13 regulates the
differentiation of specific neurons [70].
Fig. 7 HOX and SOX signature distinguishing 1p/19q from IDHme. Average log-fold expression differences of HOX and SOX genes between the
1p/19q and the IDHme subgroup. Genes downregulated in 1p/19q compared to IDHme are shown in blue and upregulated genes are shown in
red. Gene expression differences between tumors of both groups were highly significant with q-values clearly less than 0.01 (Additional file 6)
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Discussion
First, we analyzed gene copy number data of histologically
classified oligodendrogliomas from TCGA and revealed
three molecular subgroups by hierarchical clustering of
gene copy number data alone (Fig. 1). We used additional
information about the presence of a 1p/19q co-deletion
[8] and an IDH mutation [11] to further characterize
these subgroups. In accordance with previous findings
for histologically classified oligodendrogliomas [10, 71]
and gliomas in general [19], we observed a large 1p/19q
subgroup characterized by concurrent 1p/19q co-deletion
and IDH mutation, an intermediate IDHme subgroup of
tumors that mainly show an IDH mutation but no com-
monly overrepresented gene copy number alterations, and
a small 7a10d subgroup showing a concurrent duplication
of chromosome 7 and a deletion of chromosome 10 where
most tumors lacked IDH mutations. In addition, consid-
ering Verhaak [26] and G-CIMP [15] classes, the 1p/19q
and the IDHme subgroup resembled each other, whereas
the 7a10d subgroup strongly deviated from these two sub-
groups also in terms of significantly lower overall patient
survival (Fig. 2). This, in combination with the molecular
characteristics of the 7a10d subgroup, suggests that these
tumors might rather represent glioblastoma-like tumors
[3]. This is also supported by a refined molecular classifi-
cation of gliomas in [20]. Thus, tumors of our small 7a10d
subgroup may have been falsely classified as oligoden-
drogliomas based on histology alone, which is not unlikely
considering difficulties of pure histological classifications
[6]. We therefore decided to focus our further analyses on
the comparison of the 1p/19q and the IDHme subgroups.
Second, we performed an in-depth analysis of the
1p/19q and IDHme subgroups deriving a characteristic
gene expression signature that distinguished tumors of
both groups (Fig. 3). Interestingly, many of these signa-
ture genes were part of signaling pathways involved in
the regulation of cell proliferation, differentiation, migra-
tion, and cell-cell contacts (Fig. 4). Several of these path-
ways have already been reported to be involved in glioma
development (e.g. PI3K-AKT, MAPK, VEGF signaling)
[27, 33, 72, 73]. The strong downregulation of these path-
ways in the 1p/19q subgroup compared to the IDHme
subgroup might be associated with a better sensitivity to
treatment and prognosis of (1p/19q) oligodendrogliomas
compared to other low-grade gliomas [74, 75].
Third, to better understand differences between the
1p/19q and the IDHme subgroup, we reconstructed
a gene regulatory network capable to explain gene
expression differences between both subgroups (Figs. 5
and 6). Interestingly, we revealed that several poten-
tial hub transcription factors involved in remodeling of
the cytoskeleton (e.g. APBB1IP, VAV1, ARPC1B), apop-
tosis (CCNL2, CREB3L1), and neural development (e.g.
MYTIL, SCRT1, MEF2C) were differentially expressed
between both subgroups. Since all or the vast majority
of tumors of these two subgroups show IDH mutations,
the globally observed expression differences are likely to
be strongly influenced by the 1p/19q co-deletion. More-
over, we observed characteristic expression differences
between HOX and SOX transcription factors (Fig. 7). All
HOX genes included in our network were downregulated
and all SOX genes were upregulated in 1p/19q com-
pared to IDHme. This indicates that the 1p/19q subgroup
and the IDHme subgroup express different stemness pro-
grams. Recent findings of specific HOX and SOX gene
expression patterns for different types of gliomas indicate
an important role of both gene families in brain tumors
[20–22]. This is also supported by the recent finding
that SOX2 repression is an early driver of gliomagenesis
that blocks the differentiation of neural stem cells in an
in-vitro model of low-grade astrocytomas [76]. Further
experimental studies are required to analyze our revealed
stemness signatures.
Finally, it is important to discuss the revealed molecular
subtypes in the light of the new WHO 2016 brain tumor
classification scheme [18]. All oligodendrogliomas that
we analyzed have been classified by the TCGA accord-
ing to the WHO 2007 brain tumor classification scheme
[4], which was state-of-the-art when the tumors were
obtained. This older classification is purely based on his-
tology, whereas the new WHO 2016 classification addi-
tionally considers the 1p/19q-co-deletion and the IDH
mutation status. There would be differences in the group-
ing of tumors, but a reclassification of the analyzed tumors
is not straightforward and would require expert knowl-
edge of neuropathologists that have to consider histo-
logical and molecular data. Therefore, we cannot realize
this reclassification for the considered TCGA data set,
but we can interpret our subgroups with respect to the
new WHO 2016 classification. Considering our 7a10d
subgroup, information about the gain of chromosome
7 and the deletion of chromosome 10 are not consid-
ered at all in the new WHO 2016 classification system
[18]. Thus, tumors of these subgroup would still not be
classified as glioblastomas if no clear signs of high malig-
nancy (necrosis, pathological vascular proliferation) are
observed in histology. It is likely that such signs were
not present in nearly half of the 7a10d tumors (6 of 15),
otherwise these tumors would have been assigned the
WHO grade IV instead of grade II according to the WHO
2007 brain tumor classification system. Therefore, these
tumors of our 7a10d subgroup might rather be clas-
sified as astrocytoma IDH-wildtype or IDH-mutant (if
histological and molecular data are conclusive) or even
as oligodendroglioma, NOS (if histological and molecu-
lar data are inconclusive) according to the WHO 2016
brain tumor classification system. This may change in
future [77]. Such low-grade gliomas without any signs of
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high malignancy and without IDH mutation still repre-
sent an area of ongoing research [78]. Further, like for
the WHO 2007 brain tumor classification, all tumors of
our 1p/19q subgroup would also be classified as oligoden-
drogliomas (IDH-mutant and 1p/19q-codeleted) accord-
ing to the WHO 2016 brain tumor classification system.
This is also supported by the characteristic overexpression
of SOX genes. In contrast, tumors of our IDHme subgroup
would now be classified as astrocytoma IDH-mutant or
IDH-wildtype also when oligodendroglia-like features are
present in histology. This is further supported by the pres-
ence of characteristic ATRX (30 of 45 tumors) or TP53
(35 of 45 tumors) mutations in IDH-mutated tumors [18].
It is important to note that the new WHO 2016 brain
tumor classification system does not change the results
of our study. The observed molecular differences between
subgroups exist independent of the underlying classifi-
cation system. Still, one should always be aware of the
underlying classification system. In the light of the new
WHO 2016 brain tumor classification system, we per-
formed an in-depth comparison of oligodendrogliomas
(IDH-mutant and 1p/19q co-deleted) represented by our
1p/19q subgroup to astrocytomas (vast majority IDH-
mutant) represented by our IDHme subgroup. This is sup-
ported by our finding that the 1p/19q subgroup expressed
an oligodendrocyte-like program and that the IDHme
subgroup expressed an astrocyte-like program [22].
Conclusions
Our study confirms prior findings about the molecular
subtyping of histologically classified oligodendrogliomas
and further provides novel insights into gene expres-
sion differences between subtypes. It is important to
note that we were able to derive these subtypes purely
based on gene copy number data alone. Additional infor-
mation about the presence of a 1p/19q co-deletion and
an IDH mutation were only considered subsequently to
further characterize these subgroups. The in-depth com-
parison of the 1p/19q and IDHme subgroups provides
novel insights into differences at the level of single genes,
pathways, and regulatory networks that have not been
reported so far.We identified a characteristic gene expres-
sion signature that distinguishes both subgroups includ-
ing several known signaling pathways that impact on cell
proliferation, migration, and angiogenesis. We derived a
gene regulatory network that can explain expression dif-
ferences between both subgroups. Our network-based
analysis enabled us to predict novel putative major regu-
lators that contribute to the manifestation of differences
between both subgroups. Several of these major regu-
lators are known to be involved in the regulation of
cytoskeleton remodeling, apoptosis, and neural develop-
ment. Moreover, we also revealed a characteristic HOX
and SOX gene expression signature that distinguishes
both subgroups suggesting the activity of different glioma
stemness programs.
Further, the analyzed oligodendroglioma data set rep-
resents an important resource for future research, but
researchers have to be aware that these tumors were
classified by TCGA according to the WHO 2007 brain
tumor classification system. We hope that the discussion
of our findings in the context of the new WHO 2016
classification will raise awareness for the fact that brain
tumor classification systems can vary considerably. This
is important for the interpretation of the results of our
retrospective study and for future studies based on the
considered TCGA data set.
In summary, our in-depth study focused on the analysis
of molecular data of histologically classified oligoden-
drogliomas. Especially with respect to an oligodendroglial
phenotype, characteristic expression differences associ-
ated with histological classification may also exist for
other types of gliomas. Future studies with already exist-
ing molecular data of histologically classified oligoden-
drogliomas, oligoastrocytomas, and astrocytomas could
search for such patterns and evaluate their value for
molecular tumor classification.
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